(c) 2024 PillSync.com

bosentan 125 MG Oral Tablet

1 INDICATIONS AND USAGE Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) ] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) ( 1 ). in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability ( 1 ).

actavis pharma, inc.


4 years ago OVAL ORANGE WPI 125 bosentan 125 MG Oral Tablet

OVAL ORANGE WPI 125

16 HOW SUPPLIED/STORAGE AND HANDLING

BOSENtan Tablets are available as follows: 62.5 mg – Light orange, round, biconvex, film-coated tablets, debossed with ‘WPI’ on one side and ‘62.5’ on the other side contains 64.541 mg of

BOSENtan monohydrate, equivalent to 62.5 mg of

BOSENtan base. Tablets are supplied in bottles of 60 (NDC 0591-2511-60) with a child-resistant closure. 125 mg – Light orange, oval, biconvex, film-coated tablets, debossed with ‘WPI’ on one side and ‘125’ on the other side contains 129.082 mg of

BOSENtan monohydrate, equivalent to 125 mg of

BOSENtan base. Tablets are supplied in bottles of 60 (NDC 0591-2512-60) with a child-resistant closure. Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP. Keep this and all medications out of the reach of children.


More pills like OVAL WPI 125

Related Pills

bosentan 62.5 MG Oral Tablet

actavis pharma, inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site